Hee Jeong Kim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4554660/publications.pdf

Version: 2024-02-01

115 papers	1,682 citations	361413 20 h-index	361022 35 g-index
127 all docs	127 docs citations	127 times ranked	2358 citing authors

#	Article	IF	Citations
1	Functional Impairments in the Mental Health, Depression and Anxiety Related to the Viral Epidemic, and Disruption in Healthcare Service Utilization among Cancer Patients in the COVID-19 Pandemic Era. Cancer Research and Treatment, 2022, 54, 671-679.	3.0	19
2	Oncologic outcomes of immediate breast reconstruction in young women with breast cancer receiving neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2022, 191, 345-354.	2.5	4
3	Surgical Treatment After Neoadjuvant Systemic Therapy in Young Women With Breast Cancer. Annals of Surgery, 2022, 276, 173-179.	4.2	20
4	Breast cancer outcomes following immediate breast reconstruction with implants versus autologous flaps: a propensity score-matched study. Breast Cancer Research and Treatment, 2022, 191, 365-373.	2.5	3
5	The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. Breast, 2022, 61, 77-83.	2.2	38
6	Chemotherapy for ipsilateral breast tumor recurrence: a propensity score-matching study. Breast Cancer Research and Treatment, 2022, 192, 143-152.	2.5	1
7	Abstract P2-13-42: Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial. Cancer Research, 2022, 82, P2-13-42-P2-13-42.	0.9	1
8	Abstract P4-09-03: Factors affecting the parentingstressand depressioninyoung women with breast cancer. Cancer Research, 2022, 82, P4-09-03-P4-09-03.	0.9	0
9	Abstract P4-10-18: The effects of preoperative personalized music therapy associated with the patient-doctor relationship and surgical experience of patients with breast cancer (MARS). Cancer Research, 2022, 82, P4-10-18-P4-10-18.	0.9	0
10	Improvement of survival in Korean breast cancer patients over a 14-year period: A large-scale single-center study. PLoS ONE, 2022, 17, e0265533.	2.5	2
11	Mammographically occult breast cancers detected with AI-based diagnosis supporting software: clinical and histopathologic characteristics. Insights Into Imaging, 2022, 13, 57.	3.4	7
12	The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer. Cancer Research and Treatment, 2022, 54, 1111-1120.	3.0	1
13	Clinical Course and Predictors of Subsequent Recurrence and Survival of Patients With Ipsilateral Breast Tumor Recurrence. Cancer Control, 2022, 29, 107327482210894.	1.8	1
14	Is There a Difference in the Diagnosis and Prognosis of Local Recurrence between Autologous Tissue and Implant-Based Breast Reconstruction?. Breast Journal, 2022, 2022, 1-8.	1.0	0
15	Clinicopathological characteristics and outcomes of malignant adenomyoepithelioma of the breast: a single institutionâ€™s experience. World Journal of Surgical Oncology, 2022, 20, 128.	1.9	3
16	Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. Journal of the National Cancer Institute, 2022, 114, 1117-1126.	6.3	3
17	Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer. Scientific Reports, 2022, 12, 7858.	3.3	3
18	Breast density reduction as a predictor for prognosis in premenopausal women with hormone receptorâ€“positive breast cancer: A retrospective analysis of the ASTRRA study.. Journal of Clinical Oncology, 2022, 40, 531-531.	1.6	0

#	Article	IF	Citations
19	Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial.. Journal of Clinical Oncology, 2022, 40, 506-506.	1.6	10
20	The role of postoperative radiotherapy after primary tumor resection in patients with de novo stage IV breast cancer. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 495-505.	1.1	6
21	Long-term survival outcomes of repeat lumpectomy for ipsilateral breast tumor recurrence: a propensity score-matched analysis. Breast Cancer Research and Treatment, 2021, 185, 155-164.	2.5	8
22	Breast-conserving surgery with 3D-printed surgical guide: a single-center, prospective clinical study. Scientific Reports, 2021, 11, 2252.	3.3	10
23	Targeted eicosanoids profiling reveals a prostaglandin reprogramming in breast Cancer by microRNA-155. Journal of Experimental and Clinical Cancer Research, 2021, 40, 43.	8.6	15
24	Survival of Breast-Conserving Surgery Plus Radiotherapy versus Total Mastectomy in Early Breast Cancer. Annals of Surgical Oncology, 2021, 28, 5039-5047.	1.5	18
25	Oncologic Safety of Nipple-Sparing Mastectomy in Patients with Breast Cancer and Tumor-to-Nipple Distanceâ€‰â‰â€‰1Âcm: A Matched Cohort Study. Annals of Surgical Oncology, 2021, 28, 4284-4291.	1.5	16
26	Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2021, 187, 447-454.	2.5	1
27	Usefulness of 3D-surgical guides in breast conserving surgery after neoadjuvant treatment. Scientific Reports, 2021, 11, 3376.	3.3	7
28	A propensity score-matched comparison of recurrence outcomes after immediate implant vs autologous flap reconstruction in patients receiving neoadjuvant chemotherapy for breast cancer. Breast Cancer Research and Treatment, 2021, 187, 417-425.	2.5	4
29	Data on distant metastasis and survival after locoregional recurrence following nipple-sparing mastectomy and immediate breast reconstruction. Data in Brief, 2021, 35, 106837.	1.0	0
30	Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy. Scientific Reports, 2021, 11, 9056.	3.3	9
31	Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy. PLoS ONE, 2021, 16, e0251597.	2.5	6
32	Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer. Scientific Reports, 2021, 11, 10510.	3.3	3
33	Comparison of survival outcomes for axillary surgery extent based on intraoperative sentinel lymph node biopsy result after neoadjuvant chemotherapy for breast cancer. Breast Cancer Research and Treatment, 2021, 187, 647-655.	2.5	2
34	Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study. Frontiers in Oncology, 2021, 11, 636378.	2.8	9
35	Locoregional recurrence following nipple-sparing mastectomy with immediate breast reconstruction: Patterns and prognostic significance. European Journal of Surgical Oncology, 2021, 47, 1309-1315.	1.0	13
36	Impact of Local Breast Cancer Recurrence on Reconstructed Breast in Nipple-Sparing Mastectomy with Immediate Reconstruction. Journal of Plastic, Reconstructive and Aesthetic Surgery, 2021, , .	1.0	0

#	Article	IF	Citations
37	Factors Predicting Locoregional Recurrence After Neoadjuvant Chemotherapy and Nipple-Sparing/Skin-Sparing Mastectomy With Immediate Breast Reconstruction. Frontiers in Oncology, 2021, 11, 675955.	2.8	1
38	Association between Oncotype DX recurrence score and dynamic contrast-enhanced MRI features in patients with estrogen receptor-positive HER2-negative invasive breast cancer. Clinical Imaging, 2021, 75, 131-137.	1.5	5
39	Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. Frontiers in Oncology, 2021, 11, 608207.	2.8	1
40	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2021, 39, 3293-3305.	1.6	70
41	Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. Frontiers in Oncology, 2021, 11, 741120.	2.8	2
42	Breast Cancer Statistics in Korea, 2018. Journal of Breast Cancer, 2021, 24, 123.	1.9	58
43	Association of mammography and ultrasound features with MammaPrint in patients with estrogen receptor-positive, HER2-negative, node-positive invasive breast cancer. Acta Radiologica, 2021, 62, 1592-1600.	1.1	2
44	Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Cancers, 2021, 13, 6267.	3.7	7
45	A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer. Scientific Reports, 2021, 11, 23509.	3.3	6
46	Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial. Journal of Clinical Oncology, 2020, 38, 434-443.	1.6	52
47	Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancer. Breast Cancer Research and Treatment, 2020, 179, 315-324.	2.5	5
48	Is asymptomatic surveillance beneficial after standard treatment? A 10â€year survival analysis of recurrent BC patients by detection method of recurrence. Breast Journal, 2020, 26, 556-559.	1.0	1
49	The effects of poloxamer and sodium alginate mixture (Guardix-SGÂ®) on range of motion after axillary lymph node dissection: A single-center, prospective, randomized, double-blind pilot study. PLoS ONE, 2020, 15, e0238284.	2.5	5
50	Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients. Scientific Reports, 2020, 10, 17466.	3.3	11
51	Potential of MALDI-TOF-based serum N-glycan analysis for the diagnosis and surveillance of breast cancer. Scientific Reports, 2020, 10, 19136.	3.3	10
52	Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. Breast Cancer Research, 2020, 22, 54.	5.0	32
53	Changes in bone mineral density during 5Âyears of adjuvant treatment in premenopausal breast cancer patients. Breast Cancer Research and Treatment, 2020, 180, 657-663.	2.5	3
54	Breast cancer diagnosis by analysis of serum N-glycans using MALDI-TOF mass spectroscopy. PLoS ONE, 2020, 15, e0231004.	2.5	11

#	Article	IF	Citations
55	A Mobile Technology for Collecting Patient-Reported Physical Activity and Distress Outcomes: Cross-Sectional Cohort Study. JMIR MHealth and UHealth, 2020, 8, e17320.	3.7	10
56	Breast Cancer Statistics in Korea in 2017: Data from a Breast Cancer Registry. Journal of Breast Cancer, 2020, 23, 115.	1.9	94
57	Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen. Journal of Breast Cancer, 2020, 23, 553.	1.9	2
58	The Impact of Androgen Receptor and Histone Deacetylase 1 Expression on the Prognosis of Ductal Carcinoma In Situ. Journal of Breast Cancer, 2020, 23, 610.	1.9	4
59	A survey investigating the current situation of the international visiting scholar program at the department of surgery in Korea. Annals of Surgical Treatment and Research, 2020, 99, 189.	1.0	0
60	A Propensity Score-matched Analysis of Long-term Oncologic Outcomes After Nipple-sparing Versus Conventional Mastectomy for Locally Advanced Breast Cancer. Annals of Surgery, 2020, Publish Ahead of Print, .	4.2	10
61	Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer with axillary node metastasis: A survey of clinical practice. Asian Journal of Surgery, 2019, 42, 314-319.	0.4	3
62	MRI-based 3D-printed surgical guides for breast cancer patients who received neoadjuvant chemotherapy. Scientific Reports, 2019, 9, 11991.	3.3	17
63	Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen. Journal of Breast Cancer, 2019, 22, 387.	1.9	3
64	Survival outcome of adjuvant endocrine therapy alone for patients with lymph node-positive, hormone-responsive, HER2-negative breast cancer. Asian Journal of Surgery, 2019, 42, 914-921.	0.4	3
65	Diagnostic accuracy and safety of 16Î±-[18F]fluoro-17Î²-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. Lancet Oncology, The, 2019, 20, 546-555.	10.7	85
66	Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer. Annals of Surgical Oncology, 2019, 26, 2166-2174.	1.5	12
67	Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort. Breast Cancer Research and Treatment, 2019, 175, 203-215.	2.5	13
68	Age-related risk factors associated with primary contralateral breast cancer among younger women versus older women. Breast Cancer Research and Treatment, 2019, 173, 657-665.	2.5	15
69	Primary Rhabdomyosarcoma of the Breast: Study of Three Cases at One Institution with a Review of Primary Breast Sarcomas. Journal of Pathology and Translational Medicine, 2019, 53, 308-316.	1.1	6
70	A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptorâ€'Positive, Human Epidermal Growth Factor 2 (HER2)â€'Negative Breast Cancer. Cancer Research and Treatment, 2019, 51, 1073-1085.	3.0	23
71	Axillary Lymph Node Dissection Does Not Improve Post-mastectomy Overall or Disease-Free Survival among Breast Cancer Patients with 1-3 Positive Nodes. Cancer Research and Treatment, 2019, 51, 1011-1021.	3.0	18
72	The Importance of Education regarding the Effects of Anticancer Treatment on Fertility and Ovarian Function in the Female Patients with Breast Cancer. Journal of Menopausal Medicine, 2019, 25, 142.	1.1	4

#	Article	IF	Citations
73	Comparing Accuracy of Mammography and Magnetic Resonance Imaging for Residual Calcified Lesions in Breast Cancer Patients Undergoing Neoadjuvant Systemic Therapy. Clinical Breast Cancer, 2018, 18, e1087-e1091.	2.4	17
74	A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer. Breast Cancer Research and Treatment, 2018, 169, 257-266.	2.5	41
75	Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy. Clinical Breast Cancer, 2018, 18, e1165-e1172.	2.4	1
76	Characteristics and prognosis of breast cancer after liver or kidney transplantation. Breast Cancer Research and Treatment, 2018, 167, 101-106.	2.5	6
77	Survival analysis according to period and analysis of the factors influencing changes in survival in patients with recurrent breast cancer: a large-scale, single-center study. Breast Cancer, 2018, 25, 639-649.	2.9	3
78	Efficacy of Pectoral Nerve Block Type II for Breast-Conserving Surgery and Sentinel Lymph Node Biopsy: A Prospective Randomized Controlled Study. Pain Research and Management, 2018, 2018, 1-8.	1.8	55
79	Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study. Journal of Breast Cancer, 2018, 21, 70.	1.9	12
80	Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: The ASTRRA study.. Journal of Clinical Oncology, 2018, 36, 502-502.	1.6	14
81	Primary Rhabdomyosarcoma of the Breast: A Report of Two Cases and Literature Review. Journal of Pathology and Translational Medicine, 2018, , .	1.1	1
82	No Association of Positive Superficial and/or Deep Margins with Local Recurrence in Invasive Breast Cancer Treated with Breast-Conserving Surgery. Cancer Research and Treatment, 2018, 50, 275-282.	3.0	13
83	Survival improvement in hormone-responsive young breast cancer patients with endocrine therapy. Breast Cancer Research and Treatment, 2017, 165, 311-320.	2.5	15
84	Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2017, 166, 473-480.	2.5	32
85	A Randomized Feasibility Study of ¹⁸F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptorâ€“Rich Postmenopausal Breast Cancer. Journal of Nuclear Medicine, 2017, 58, 563-568.	5.0	40
86	A phase III, open label, prospective, randomized, multicenter, neoadjuvant study of chemotherapy versus endocrine therapy in premenopausal patient with hormone responsive, HER2 negative, breast cancer (KBCSG 012).. Journal of Clinical Oncology, 2017, 35, 517-517.	1.6	1
87	Interaction between body mass index and hormone-receptor status as a prognostic factor in lymph-node-positive breast cancer. PLoS ONE, 2017, 12, e0170311.	2.5	15
88	Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer. British Journal of Cancer, 2016, 114, 1109-1116.	6.4	37
89	Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer. Breast Cancer, 2016, 23, 771-779.	2.9	18
90	Patient reporting pain intensity immediately after surgery can be associated with underlying depression in women with breast cancer. Psycho-Oncology, 2016, 25, 308-315.	2.3	15

#	Article	IF	Citations
91	Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Nodeâ€“Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer. Cancer Research and Treatment, 2016, 48, 1351-1362.	3.0	6
92	Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes. Breast Cancer Research, 2015, 17, 64.	5.0	66
93	Concurrent Gonadotropin-Releasing Hormone Agonist Administration with Chemotherapy Improves Neoadjuvant Chemotherapy Responses in Young Premenopausal Breast Cancer Patients. Journal of Breast Cancer, 2015, 18, 365.	1.9	14
94	A proposal for a new classification of T4 breast cancer as stage IIIC: a report from the Korean Breast Cancer Society. Breast Cancer Research and Treatment, 2015, 153, 153-160.	2.5	8
95	Neutrophil lymphocyte ratio (NLR) change after systemic treatment as a predictive factor of cancer specific survival in stage IV breast cancer.. Journal of Clinical Oncology, 2015, 33, 29-29.	1.6	2
96	Approach to Serial Liquid Biopsy: Enrichment of circulating tumor cells (CTC) in breast cancer patients for cancer panel analysis.. Journal of Clinical Oncology, 2015, 33, e22029-e22029.	1.6	0
97	A proposal for a new classification of T4 breast cancer as stage IIIC.. Journal of Clinical Oncology, 2015, 33, e11585-e11585.	1.6	0
98	Prognosis of breast cancer as a result of late recurrence in hormone receptor-positive tumor.. Journal of Clinical Oncology, 2015, 33, e11587-e11587.	1.6	0
99	Survival Outcomes of Different Treatment Methods for the Ipsilateral Breast of Occult Breast Cancer Patients with Axillary Lymph Node Metastasis: A Single Center Experience. Journal of Breast Cancer, 2013, 16, 410.	1.9	11
100	Stage, biology, and age.. Journal of Clinical Oncology, 2013, 31, e11512-e11512.	1.6	0
101	Claudin 1, 3, 4, and 7 expression in triple-negative breast cancer.. Journal of Clinical Oncology, 2013, 31, 1070-1070.	1.6	16
102	Predictive factors of no response during neoadjuvant chemotherapy in breast cancer.. Journal of Clinical Oncology, 2012, 30, e11508-e11508.	1.6	0
103	Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status. Breast, 2011, 20, 78-85.	2.2	62
104	Vitamin D Deficiency is Correlated with Poor Outcomes in Patients with Luminal-type Breast Cancer. Annals of Surgical Oncology, 2011, 18, 1830-1836.	1.5	73
105	Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society. Breast Cancer Research and Treatment, 2011, 130, 507-515.	2.5	46
106	Young age is associated with ipsilateral breast tumor recurrence after breast conserving surgery and radiation therapy in patients with HER2-positive/ER-negative subtype. Breast Cancer Research and Treatment, 2011, 130, 499-505.	2.5	31
107	Nipple Areola Skin-Sparing Mastectomy With Immediate Transverse Rectus Abdominis Musculocutaneous Flap Reconstruction is an Oncologically Safe Procedure. Annals of Surgery, 2010, 251, 493-498.	4.2	98
108	Sentinel node biopsy in patients with multiple breast cancer. Breast Cancer Research and Treatment, 2008, 109, 503-506.	2.5	28

#	Article	IF	Citations
109	Experience of Ovarian Function Suppression Therapy: Endocrine Response Preand Perimenopausal Korean Breast Cancer Patients in the Adjuvant Setting. Journal of Breast Cancer, 2007, 10, 134.	1.9	0
110	Result of Sentinel Lymph Node Biopsy Using Radioisotope in Clinically Lymph Node Negative Breast Cancer. Journal of Breast Cancer, 2007, 10, 141.	1.9	7
111	Comparison of Early Postoperative Axillary Morbidity Following the Sentinel Lymph Node Biopsy or Axillary Lymph Node Dissection. Journal of Breast Cancer, 2007, 10, 107.	1.9	1
112	Pulmonary Thromboembolism following Mastectomy with Immediate TRAM in the Patients with Breast Cancer: a Prospective Study. Journal of Breast Cancer, 2006, 9, 354.	1.9	11
113	Relationship of Bone mineral density and the risk of breast cancer in Korean postmenopausal women. Journal of Breast Cancer, 2006, 9, 330.	1.9	3
114	The Recurrence Rate, Risk Factors and Recurrence Patterns after Surgery in 3700 Patients with Operable Breast Cancer. Journal of Breast Cancer, 2006, 9, 134.	1.9	15
115	Surgical Treatment of Locoregional Recurrence in Breast Cancer. Journal of Breast Cancer, 2006, 9, 241.	1.9	1